Abbott, Amgen are on the prowl with small deals
Posted on December 15, 2009 at 12:00 PM EST
DailyFinance : Acquisitions and deals are always a risky business, especially in the pharmaceuticals industry. Just today, Elan Corp. (ELN) and Gilead Sciences (GILD) discovered the price of such deals when both halted drug trials on compounds developed by other ... Read more